Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Promacta eltrombopag: Phase II data

In a Phase II trial (TPL102357) in 74 patients, all doses of eltrombopag met the primary endpoint of platelet counts >=100,000/µL at

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE